Login Register Cart 0
Generic placeholder image

Letters in Drug Design & Discovery

Editor-in-Chief

ISSN (Print): 1570-1808
ISSN (Online): 1875-628X

Back
Research Article

An In-silico Approach to Identify Potential Drug Molecules for Alzheimer’s Disease: A Case Involving Four Therapeutic Targets

Author(s): Smitha Sunil Kumaran Nair*, Rajamohamed Beema Shafreen, Saqar Said Nasser Al Maskari, Nallusamy Sivakumar, Kiran Gopakumar Rajalekshmi and Adhraa Al Mawaali

Volume 19, Issue 6, 2022

Published on: 08 March, 2022

Page: [541 - 548] Pages: 8

DOI: 10.2174/1570180819666220124114100

Price: $65

Abstract

Background: Computational methods in the ‘omics’ era have proved to be a boon in the drug discovery field. Bioinformatics and cheminformatics databases and tools complement the successful discovery of promising lead compounds in the treatment of several disease conditions, including neurodegenerative diseases, such as Alzheimer’s Disease (AD). However, commercially available drugs in the market to alleviate the disease progression in AD patients are sparse. The current research aims to apply an in-silico approach involving multi-therapeutic agents against multi-therapeutic targets through docking studies to explore potential lead compounds for AD clinical trials.

Method: In the proposed research, virtual screening was performed on four US FDA-approved control drugs (donepezil (DON), galantamine (GAL), rivastigmine (RIV), and tacrine (TAC)) in order to be used for mild-moderate-severe stages of AD treatment. The panel of compounds identified through virtual screening was assessed for chemical absorption, distribution, metabolism, excretion, and toxicity (ADMET) and Pharmacokinetics (PK). The compound with good ADMET and PK score was investigated further with molecular docking against the four therapeutic targets involved in AD. Ligands showing the highest binding affinity against cholinesterase inhibitors (AChE, BuChE), receptor antagonists (NMDA), and β-amyloid peptide (Aβ), were computed.

Result: The compounds quinazolidinone analogue, 2b, isoquinoline-pyridine, 1, benzylmorphine and coelenteramide, were found to be the lead candidates having least side effects and better efficacy.

Conclusion: The predicted lead candidates are suitable for further investigation in the drug discovery pipeline.

Keywords: Alzheimer’s disease, FDA-approved drugs, molecular docking, therapeutic targets, virtual screening.

« Previous Next »
Graphical Abstract

[1]
Dementia. Available from: https://www.who.int/news-room/fact-sheets/detail/dementia
[2]
Potshangbam, A.M.; Nandeibam, A.; Amom, T.; Potshangbam, N.; Rahaman, H.; Rathore, R.S.; Singh, L.R.; Khan, A. An in silico approach to identify potential medicinal plants for treating Alzheimer disease: a case study with acetylcholinesterase. J. Biomol. Struct. Dyn., 2020, 1-13.
[http://dx.doi.org/10.1080/07391102.2020.1828170] [PMID: 33021148]
[3]
Kumar, S.; Chowdhury, S.; Kumar, S. In silico repurposing of antipsychotic drugs for Alzheimer’s disease. BMC Neurosci., 2017, 18(1), 76.
[http://dx.doi.org/10.1186/s12868-017-0394-8] [PMID: 29078760]
[4]
Ortega, S.S.; Cara, L.C.L.; Salvador, M.K. In silico pharmacology for a multidisciplinary drug discovery process. Drug Metabol. Drug Interact., 2012, 27(4), 199-207.
[http://dx.doi.org/10.1515/dmdi-2012-0021] [PMID: 23152402]
[5]
Intelligent drug discovery. 2019. Available from: https://www2.deloitte.com/us/en/insights/industry/life-sciences/artificial-intelligence-biopharma-intelligent-drug-discovery.html
[6]
Chaudhary, A.; Maurya, P.K.; Yadav, B.S.; Singh, S.; Mani, A. Current therapeutic targets for Alzheimer’s disease. J. Biomed. (Syd.), 2018, 3, 74-84.
[http://dx.doi.org/10.7150/jbm.26783]
[7]
Jamal, S.; Grover, A. Cheminformatics approaches in modern drug discovery. In: Drug Design: Principles and Applications; Springer Singapore: Singapore, 2017; pp. 135-148.
[http://dx.doi.org/10.1007/978-981-10-5187-6_9]
[8]
Alam, J.; Sharma, L. Potential enzymatic targets in Alzheimer’s: A comprehensive review. Curr. Drug Targets, 2019, 20(3), 316-339.
[http://dx.doi.org/10.2174/1389450119666180820104723] [PMID: 30124150]
[9]
Ivanova, L.; Karelson, M.; Dobchev, D.A. Multitarget approach to drug candidates against Alzheimer’s disease related to AChE, SERT, BACE1 and GSK3β protein targets. Molecules, 2020, 25(8), E1846.
[http://dx.doi.org/10.3390/molecules25081846] [PMID: 32316402]
[10]
Choi, R.J.; Roy, A.; Jung, H.J.; Ali, M.Y.; Min, B-S.; Park, C.H.; Yokozawa, T.; Fan, T.P.; Choi, J.S.; Jung, H.A. BACE1 molecular docking and anti-Alzheimer’s disease activities of ginsenosides. J. Ethnopharmacol., 2016, 190, 219-230.
[http://dx.doi.org/10.1016/j.jep.2016.06.013] [PMID: 27275774]
[11]
Onoja, OJ; Elufioye, TO; Sherwani, ZA; Ul-Haq, Z Molecular docking studies and anti-Alzheimer’s potential of isolated compounds from Tinospora cordifolia. J. Biol. Act. Prod. Nat., 2020, 10(2), 100-121.
[12]
Rodriguez, S.; Hug, C.; Todorov, P.; Moret, N.; Boswell, S.A.; Evans, K.; Zhou, G.; Johnson, N.T.; Hyman, B.T.; Sorger, P.K.; Albers, M.W.; Sokolov, A. Machine learning identifies candidates for drug repurposing in Alzheimer’s disease. Nat. Commun., 2021, 12(1), 1033.
[http://dx.doi.org/10.1038/s41467-021-21330-0] [PMID: 33589615]
[13]
Knowles, J. Donepezil in Alzheimer’s disease: An evidence-based review of its impact on clinical and economic outcomes. Core Evid., 2006, 1(3), 195-219.
[PMID: 22500154]
[14]
Zoete, V.; Daina, A.; Bovigny, C.; Michielin, O. SwissSimilarity: A web tool for low to ultra-high throughput ligand-based virtual screening. J. Chem. Inf. Model., 2016, 56(8), 1399-1404.
[http://dx.doi.org/10.1021/acs.jcim.6b00174] [PMID: 27391578]
[15]
PubChem. Available from: https://pubchem.ncbi.nlm.nih.gov/
[16]
Yang, M.; Chen, J.; Xu, L.; Shi, X.; Zhou, X.; Xi, Z. A novel adaptive ensemble classification framework for ADME prediction. RSC Advances, 2018, 8(21), 11661-11683.
[http://dx.doi.org/10.1039/C8RA01206G]
[17]
SwissADME. Available from: http://www.swissadme.ch/
[18]
Yang, H.; Lou, C.; Sun, L.; Li, J.; Cai, Y.; Wang, Z.; Li, W.; Liu, G.; Tang, Y. admetSAR 2.0: Web-service for prediction and optimization of chemical ADMET properties. Bioinformatics, 2019, 35(6), 1067-1069.
[http://dx.doi.org/10.1093/bioinformatics/bty707] [PMID: 30165565]
[19]
Pires, D.E.V.; Blundell, T.L.; Ascher, D.B. PkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J. Med. Chem., 2015, 58(9), 4066-4072.
[http://dx.doi.org/10.1021/acs.jmedchem.5b00104] [PMID: 25860834]
[20]
Shoaib, M.; Kamal, M.A.; Rizvi, S.M.D. Repurposed drugs as potential therapeutic candidates for the management of Alzheimer’s disease. Curr. Drug Metab., 2017, 18(9), 842-852.
[http://dx.doi.org/10.2174/1389200218666170607101622] [PMID: 28595531]
[21]
D’Ursi, A.M.; Armenante, M.R.; Guerrini, R.; Salvadori, S.; Sorrentino, G.; Picone, D. Solution structure of amyloid beta-peptide (25-35) in different media. J. Med. Chem., 2004, 47(17), 4231-4238.
[http://dx.doi.org/10.1021/jm040773o] [PMID: 15293994]
[22]
Yamin, G.; Ono, K.; Inayathullah, M.; Teplow, D.B. Amyloid beta-protein assembly as a therapeutic target of Alzheimer’s disease. Curr. Pharm. Des., 2008, 14(30), 3231-3246.
[http://dx.doi.org/10.2174/138161208786404137] [PMID: 19075703]
[23]
RCSB protein data bank. RCSB PDB: Homepage. Available from: https://www.rcsb.org/
[24]
Morris, G.M. AutoDock — AutoDock. Available from: http://autodock.scripps.edu/

Rights & Permissions Print Cite
Article Metrics
17
1
© 2024 Bentham Science Publishers | Privacy Policy